自然review
REVIEWS
The FGF family: biology,
pathophysiology and therapy
Andrew Beenken and Moosa Mohammadi
Abstract | The family of fibroblast growth factors (FGFs) regulates a plethora of
developmental processes, including brain patterning, branching morphogenesis and limb development. Several mitogenic, cytoprotective and angiogenic therapeutic applications of FGFs are already being explored, and the recent discovery of the crucial roles of the endocrine-acting FGF19 subfamily in bile acid, glucose and phosphate homeostasis has sparked renewed interest in the pharmacological potential of this family. This Review discusses traditional applications of recombinant FGFs and small-molecule FGF receptor kinase inhibitors in the treatment of cancer and cardiovascular disease and their emerging potential in the treatment of metabolic syndrome and hypophosphataemic diseases.
Autosomal dominant
hypophosphataemic rickets
A hereditary disorder of phosphate wasting characterized by rickets, lower extremity deformities and osteomalacia.
Lacrimo-auriculo-dento-digital syndrome
(LADD). A syndrome
characterized by abnormalities of the digits and teeth, low-set ears and aplasia of the lacrimal and salivary glands. Mutations in FGFR2 and FGF10 are known to cause LADD.
Kallmann syndrome
This syndrome results from a deficiency of gonadotropin-releasing hormone, which leads to hypogonadism. Mutations in FGFR1c and FGF8 are known to cause Kallmann syndrome.
Department of
Pharmacology, New York
University School of Medicine, New York, New York 10016, USA.
e-mails: ;
doi:10.1038/nrd2792
There are 18 mammalian fibroblast growth factors (FGF1–FGF10 and FGF16–FGF23) which are grouped into 6 subfamilies based on differences in sequence homology and phylogeny: and ; FGF3, FGF7, FGF10, FGF22; , FGF5 and FGF6; , FGF17 and FGF18; , FGF16 and FGF20; and , FGF21 and FGF23 (REF. 1). The numbered ‘FGFs’ that are unassigned to subfamilies — the FGF homologous factors (previously known as FGF11–FGF14) — have high sequence identity with the FGF family but do not activate FGF receptors (FGFRs) and are therefore not generally considered members of the FGF family2 (BOX 1); FGF15 is the mouse orthologue of human FGF19. FGFs are classi-cally considered to be paracrine factors and are known for their roles in tissue patterning and organogenesis during embryogenesis: the first five subfamilies fall into this category. By contrast, the FGF19, FGF21 and FGF23 subfamily has recently been shown to function in an endocrine manner, dependent on the presence of klotho proteins in their target tissues, to regulate bile acid, choles-terol, glucose, vitamin D and phosphate homeostasis3–6.The involvement of FGF signalling in human disease is well documented. Deregulated FGF signalling can con-tribute to pathological conditions either through gain- or loss-of-function mutations in the ligands themselves — for example, FGF23 gain of function in autosomal dominant hypophosphataemic rickets7, FGF10 loss of function in lacrimo-auriculo-dento-digital syndrome (LADD syn-drome)8, FGF3 loss of function in deafness9 and FGF8 loss of function in Kallmann syndrome10 — or through gain- or loss-of-function mutations in FGFRs, which contribute to many skeletal syndromes41, Kallmann
syndrome36, LADD syndrome54 and cancer. Therapeutic approaches using exogenous FGFs, antibodies or small molecules are still relatively new, and many avenues of investigation remain open. Recombinant is already in use for the treatment of chemoradiation-induced oral mucositis. Future application of the FGFs in renal disease, glucose and phosphate homeostasis, stem cell research, tissue repair and bioengineering, and angiogenesis is expected. Continued efforts to understand the structural biology of FGF–FGFR interactions will play a key part in driving the discovery of new therapies.
In this article, we briefly review current knowledge regarding FGF–FGFR signalling and then focus on the biology, pathology and recent developments regarding the pharmacological applications of each ligand.
The FGF–FGFR signalling system
FGFs. All FGFs, except those in subfamilies FGF1 and FGF2, and FGF9, FGF16 and FGF20, have signal peptides. The FGF9, FGF16 and FGF20 subfamily is nonetheless secreted through the traditional endoplasmic reticulum (ER)–Golgi secretory pathway11, whereas the FGF1 and FGF2 subfamily is secreted independently12. FGFs have a homologous core region that consists of 120–130 amino acids ordered into 12 antiparallel β-strands (β1–β12) flanked by divergent amino and carboxyl termini (FIG. 1a). In general, primary sequence variation of the N- and C-terminal tails of FGFs accounts for the differ-ent biology of the ligands13 (FIG. 1b). The heparan sulphate glycosaminoglycan (HSGAG) binding site (HBS) within the FGF core is composed of the β1–β2 loop and parts of the region spanning β10 and β12. For paracrine FGFs,
Drug Discovery
Photon Microscopy to Understand Kidney Injury and ...the pathophysiology and therapy of kidney disease ...FGF-23 能抑制肾小管上皮细胞上的钠磷(Na/Pi)共...
Proceedings: 5th International World Congress on the Pathophysiology, Immune Consequences and Therapy of Trauma, Shock and Sepsis, Munich, Germany, March ...
pathophysiology etiology prothrombin time,PT ...biology analysis of system behaviors cell signaling...the heart,VDH cardiac resynchronization therapy,CRT...
the supplement of VEGF, b-FGF, IGF-1 on ...conditions to enhance the benefit of EPCs therapy...EPCs homing and Department of Pathophysiology ...
MD Department of Physiology and Pathophysiology, Shanghai...The Biology of Cancer (? Garland Science 2007) ...evidence suggests that stem cell therapy might ...
therapy Conventional therapy The Diabetes Control and Complications Trial ...FGF, HGF,VEGF,Insulin NERVE REGENERATION/ PREVENTION OF APOPTOSIS RESTORATION ...
in hypertension research potentials vascular biology...Pathophysiology of smooth muscle in hypertension. ...Unger T.The renin-angiotensin system and its ...
pressure and in the pathophysiology of ...have never been used, except for the FGF2 [25...vessels by a myoblast-based cell therapy [33]....
Pathophysiology PTH play key roles in the ...the coordinated actions of FGF-23 and 1,25(OH...Conservative therapy used in elderly or mild ...
FGF21 analogue shows promise in the clinic_基础医学_医药卫生_专业资料。RESEARCH HIGHLIGHTS Nature Reviews Drug Discovery AOP, published online 18 October ...
热门文档